Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q36643696

about

Trial watch - inhibiting PARP enzymes for anticancer therapy Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Immune checkpoint inhibitors: therapeutic advances in melanoma Trial watch: IDO inhibitors in cancer therapy CD40 immunotherapy for pancreatic cancer Trial watch: Dendritic cell-based anticancer therapy Trial Watch-Oncolytic viruses and cancer therapy Trial Watch: Proteasomal inhibitors for anticancer therapy Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.Combinations of immunotherapy and radiation in cancer therapy.The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.Agonistic CD40 antibodies and cancer therapy.Immunotherapy in pediatric malignancies: current status and future perspectives Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.CD40 therapy and surgery: a potential immunologic partnership.Harnessing immune responses in the tumor microenvironment: all signals needed.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Mitigating the toxic effects of anticancer immunotherapy.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Immuno-regulatory antibodies for the treatment of cancer.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Designing therapeutic cancer vaccines by mimicking viral infections.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Checkpoint inhibition for colorectal cancer: progress and possibilities.Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Signaling by Antibodies: Recent Progress.Tumor-Associated Macrophages as Target for Antitumor Therapy.A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members.

P2860

Q26745673-C4417837-BB11-4093-B256-CB5246A57DA8 Q26745686-F1B7C4DD-1433-4A94-AFE6-23CC715F59F0 Q26775578-3227E0B3-3453-4099-B6DF-A2C1F04EE05E Q26775591-31D9E81D-DFD6-443F-9783-26A262700B4A Q27006866-33210889-315E-4EF1-A835-D96296126DAB Q27012550-36FEA258-132A-4FCD-807E-A87A8FAAC10F Q27024047-E0CEE2E5-D3EA-4B02-B7FD-92A65B36F03F Q28072347-1D87AA10-2B29-4B3F-A877-8523D3D39E1E Q28082910-8D3C598A-46CE-4350-951E-1F7395A4FD11 Q33805073-F1D777BE-DF17-4C6B-9A3C-AB52823E3225 Q34405616-ECC10423-EED7-409E-821C-99CC0DAD5B50 Q34458339-E09F2CEE-A631-4E53-914E-EDD3E6B345C6 Q34582640-A18B2C4C-0296-47A1-930D-2CFA58CA8B7B Q35060384-E9D5A6E6-FECF-4B15-BCB4-DDDD6736C2D0 Q35572171-7867A7BC-CD1C-42C2-9F46-84DD791B9B95 Q35864569-335C14CC-809B-434D-9D21-061292140B3E Q36664195-6C509079-EC58-4056-8B9B-19B6BE6B7EA0 Q36691818-E282D645-11DA-441E-9A7B-8BA298946890 Q37114367-C20B1D0B-60F1-420C-B52E-8B16DF6A4B4F Q37155745-8B6A7B8C-7C71-4014-95D4-642DBB808B51 Q37226420-30CA57F1-FD32-4872-9C5F-B4F1BC47BEF9 Q37340543-A2F6DEDD-B6AB-43A0-AB5A-A8A715AF1EC0 Q37652790-399C2DA2-08C5-4E02-99FA-AF32B3B7CB3F Q38162129-089669B1-4093-4237-8CBC-D655BF6AD3D8 Q38180319-21FF9684-CBAC-492F-A350-E9C3D6D6E731 Q38391533-BC39540B-1818-4880-A6DD-1539EADA6D98 Q38424617-9EDEA35B-3BDD-4B08-BDEF-2EC959BE2DFC Q38447992-FF8E70F2-A690-4DE2-8E62-6F2A5DBEC7AA Q38786054-51F92023-0119-43A9-AE78-3176DF674ED2 Q38800011-EED7A83E-8686-4027-A48D-60F4B7B7E454 Q38806038-00C4D36F-A528-4F4B-973F-E3C8E0EC0F46 Q38838641-3F4025C4-41B9-479F-8D74-62A8F8A6E45A Q39003293-07137F66-1CDE-4934-AD4C-457916480CF6 Q39022841-08643953-677A-43A2-ABCA-B176188CA7B0 Q39190801-C00494D4-3B84-489A-BF26-C095573985EA Q39264890-30CFFDC6-6CC3-42F1-A188-A0690019F092 Q39403895-B9F13D50-8A15-4EB8-A2AF-DA66E0A47CEA Q40522944-2AC4FEBC-4891-403E-B90C-F93C3FEE00D0 Q41855863-7CA0CB2A-F849-4BEB-BE31-4D25A7FD7662 Q42378925-110C5349-BBD8-4F7C-8E67-7E54A4EBD7CE

P2860

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q36643696

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@ast

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@en

type

label

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@ast

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@en

prefLabel

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@ast

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@en

P1433

Q36643696-101EA08B-C35C-4DAB-84CC-1DC5BFB2C62D

P1476

Q36643696-798CBBC9-8EAE-4BA1-9D4A-C666F97EEFB7

P2093

Q36643696-0615DAA5-6D45-45AA-BFD2-5AB894E02571

Q36643696-1CA90A09-1E2E-4E63-A6EB-5F86B2743A68

Q36643696-31AAEFCD-03CA-4B68-B93A-AE079639CC0D

Q36643696-5F9E61EF-A20F-4452-B26F-6F04B4330478

Q36643696-82170E9B-71D1-44DA-BD46-27FB301382E0

Q36643696-8683A972-D0EA-4BB2-96BF-5F61F0B3DE90

Q36643696-8E2B849E-2D68-41AE-ADC1-3FE8787FC156

Q36643696-F0788E72-439D-4781-82EB-8EBC75642BF4

P2860

Q36643696-22EE4671-D3A2-48BB-AFD0-F104BB346CA7

Q36643696-6E2FFE09-1DF3-4857-8FE2-E88710EB8110

Q36643696-7AD55838-301D-4409-AF23-027989B724DB

Q36643696-9B186D87-823E-4003-973C-E3A926851AE7

Q36643696-B81452D0-8815-48FA-9ADF-391281AD579B

Q36643696-BD4ADBA0-FC7D-403C-AA2D-668D3D4E829E

Q36643696-C770CBB1-C7F3-432F-A02C-EFF687E665AC

Q36643696-D11FBEBC-2155-4176-ACDE-F8A084E25A35

Q36643696-E03B078B-EF33-463B-8B50-DC68AF3C589C

Q36643696-FA78208B-B9C4-45A9-8CEE-7435BD72C46F

P304

Q36643696-947115B0-3A4C-46E1-AC9B-F02EC0E339D5

P31

Q36643696-8CD8EF58-CE6E-4C5E-9CC6-755ED46A59AB

P356

Q36643696-D0E66605-FA4D-4D6B-86A6-DE3B2B41B07F

P433

Q36643696-56C59D7F-6DD2-44A9-A354-5A3E2B9F4D31

P478

Q36643696-E5473A78-5879-4369-8DFF-81B36E47C096

P577

Q36643696-F95EE65B-71B4-4A0F-9180-59ADB4C33984

P5875

Q36643696-6B523BA9-45C0-49B8-B718-931FF5056ECA

P698

Q36643696-A8930CC1-5BBC-4EF4-8BF3-A4B57D33F128

P921

Q36643696-D9E2B424-6184-4181-9679-4B67D352E776

P932

Q36643696-4BA04EEF-EF4C-437F-B4D6-C70947FEFB83

P356

P1433

P1476

Phase I study of the CD40 agon ...... ts with advanced solid tumors.

@en

P2093

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Dongguang Li

http://www.w3.org/2001/XMLSchema#string

Jennifer A Trosko

http://www.w3.org/2001/XMLSchema#string

Jennifer M Burg

http://www.w3.org/2001/XMLSchema#string

M Naveed Shaik

http://www.w3.org/2001/XMLSchema#string

Omid Hamid

http://www.w3.org/2001/XMLSchema#string

Robert H Vonderheide

http://www.w3.org/2001/XMLSchema#string

Rosemarie Mick

http://www.w3.org/2001/XMLSchema#string

P2860

CD40-CD40 ligand

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.

Prospect of targeting the CD40 pathway for cancer therapy.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Role for CD40-CD40 ligand interactions in the immune response to solid tumours.

Phase II study of paclitaxel and carboplatin for malignant melanoma.

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

P304

e23033

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.23033

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236039975

http://www.w3.org/2001/XMLSchema#string

P698

23483678

http://www.w3.org/2001/XMLSchema#string

P921

P932

3583942

http://www.w3.org/2001/XMLSchema#string